Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
NCT04254263
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
316
Enrollment
OTHER
Sponsor class
Conditions
Locally Advanced Breast Cancer
Interventions
DRUG:
pyrotinib
Sponsor
RenJi Hospital